![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Israel's Teva to Partner on New Leukaemia Cell Therapy
Israel's Teva to Partner on New Leukaemia Cell Therapy
Leading Israeli drugmaker Teva has announced that it has exercised its option to enter into a joint venture with local stem-cell research firm Gamida-Cell. The two companies will develop and market the StemEx technology, which recently entered Phase I/II trials. Teva is to conditionally invest some US$25mn in the venture. The two companies hope to begin Phase II/III trials in the second half of the year.
According to Gamida-Cell, the technology uses a small molecule that enables
large-scale self-renewal of stem cells, and current tests focus on possible
applications for leukaemia and lymphoma. Israeli-European company Elscint is
reported to have been a key investor in Gamida-Cell, along with Biomedical Investments,
Denali Ventures, Auriga Ventures, Pamot and Comverse. Teva is also a leading
partner in a cell therapies development consortium known as Genesis, which has
invested in Proneuron, an Israeli cell therapy firm focusing on spinal rehabilitation.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct